DelveInsight’s ‘Epilepsy Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline epilepsy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the epilepsy pipeline domain.
For epilepsy emerging drugs, the Epilepsy pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Some of the Key Highlights from Epilepsy Pipeline Report
- Over 70+ epilepsy pipeline therapies are in various stages of growth, and their anticipated acceptance in the epilepsy market would significantly increase market revenue.
- Leading epilepsy companies such as Eisai Co.LTD., Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, CombiGene, and others are evaluating novel epilepsy treatment drugs candidate to improve the treatment landscape.
- Key epilepsy pipeline therapies in various stages of development include Perampanel, Alprazolam, XEN1101, GWP42006, EQU-001, TAK-935, Lu AG06466, OPC-214870, CG 01, and others.
- Out of the emerging epilepsy therapies, XEN1101 is in the late stage of development, whereas Lu AG06466 is in the early stage of development.
- CombiGene is currently evaluating CG 01 in the preclinical stage.
Request a sample and discover the recent advances in epilepsy therapies @ Epilepsy Pipeline Insight and Outlook
Epilepsy is a pretty common neurological disease affecting people worldwide. It affects roughly 3 million people in the United States. Epilepsy can affect anyone, but it is more frequent in children and elderly adults. It affects males slightly more than females. Epilepsy symptoms vary depending on the region of the brain where seizure activity occurs and the type of seizure. Epilepsy treatment can help most people with epilepsy have fewer seizures or totally stop experiencing seizures. The epilepsy causes are unknown In nearly half of those who have epilepsy. The specialist may recommend an electroencephalogram (EEG) test for epilepsy diagnosis to monitor the brain activity or a brain scan to look for any problems in the brain.
For more information about epilepsy drugs, visit: Epilepsy Treatment Drugs
Xenon 1101, a novel KV7 potassium channel opener, is being developed for the treatment of epilepsy. Ezogabine, an earlier generation Kv7 opener licenced by the FDA as an additional treatment for individuals with focal seizures with or without secondary generalisation, clinically verified the Kv7 potassium channel mechanism.
Soticlestat is a first-in-class, potent, highly selective inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H) with the potential to reduce seizure susceptibility and enhance seizure control. CH24H is found primarily in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to maintain the homeostatic equilibrium of brain cholesterol. 24HC is a positive allosteric modulator of the NMDA receptor that affects glutamatergic signalling in epilepsy.
Gain more knowledge on emerging epilepsy drugs @ Novel Epilepsy Drugs
Pipeline Therapies and Key Companies
- XEN496: Xenon Pharmaceuticals
- AMZ002: Amzell
- XEN1101: Xenon Pharmaceuticals
- EQU 001: Equilibre Biopharmaceuticals
- Lu AG06466: Lundbeck
- OPC-214870: Otsuka Pharmaceutical
- CG 01: CombiGene
Learn more about the FDA approved epilepsy therapies @ Epilepsy Clinical Trials
Epilepsy Pipeline Therapeutics Assessment
By Product Type
- Combination Therapy
- Phase I
- Phase II
- Phase III
By Route of Administration
By Molecule Type
- Small molecule
Scope of the Epilepsy Report
Key Epilepsy Companies: Eisai Co.LTD., Alexza Pharmaceuticals, Xenon Pharmaceuticals (NASDAQ: XENE), GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, and others
Key Epilepsy Pipeline Therapies: Perampanel, Alprazolam, XEN1101, GWP42006, EQU-001, TAK-935, Lu AG06466, OPC-214870, and others
Table of Contents
|1.||Epilepsy Pipeline Report Introduction|
|2.||Epilepsy Pipeline Report Executive Summary|
|3.||Epilepsy Pipeline: Overview|
|4.||Analytical Perspective In-depth Commercial Assessment|
|5.||Epilepsy Pipeline Therapeutics|
|6.||Epilepsy Pipeline: Late Stage Products (Pre-registration)|
|7.||Epilepsy Pipeline: Late Stage Products (Phase III)|
|8.||Epilepsy Pipeline: Mid Stage Products (Phase II)|
|9.||Epilepsy Pipeline: Early Stage Products (Phase I)|
|10.||Epilepsy Pipeline Therapeutic Assessment|
|11.||Inactive Products in the Epilepsy Pipeline|
|12.||Company-University Collaborations (Licensing/Partnering) Analysis|
|14.||Key Products in the Epilepsy Pipeline|
|16.||Market Drivers and Barriers|
|17.||Future Perspectives and Conclusion|
Got queries? Reach out for more information @ Epilepsy Pipeline Assessment
Epilepsy Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key epilepsy companies including Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, among others.
Epilepsy Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted epilepsy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Refractory Epilepsy Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key refractory epilepsy companies, including Eisai Co.LTD., Alexza Pharmaceuticals, Xenon Pharmaceuticals, among others.
Partial Epilepsy Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key partial epilepsy companies, including GW Pharmaceuticals, Equilibre Biopharmaceuticals, among others.
Refractory Epilepsy Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key refractory epilepsy companies including Eisai Co.LTD., Alexza Pharmaceuticals, Xenon Pharmaceuticals, among others.
Partial Epilepsy Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key partial epilepsy companies, including GW Pharmaceuticals, Equilibre Biopharmaceuticals, among others.
Other Trending Reports
Atopic Dermatitis Market | Peripheral Vascular Devices Market | Obsessive-Compulsive Disorder Market | Sinus Dilation Devices Market | Papilloma Market | Germ Cell Tumor Market | Portal Hypertension Market | Cell And Gene Therapy For Multiple Myeloma Market | Fallopian Tube Cancer Market | Atherectomy Devices Market | Oncolytic Virus Cancer Therapy Market | Urinary Incontinence Market | Cholangiocarcinoma Market | Tissue Heart Valves/Cardiovascular Prosthetic Devices Market | Artificial Disc Market | Obesity Market | Cerebral Infarction Market | Hematuria Market | Diabetes Market | Spinal Fusion Devices Market | Panuveitis Market | Prosthetic Heart Valve Market
Latest Healthcare Blogs
- Generalized Myasthenia Gravis Treatment Outlook
- ADPKD Market Scenario
- Leading Neurostimulation Devices for Pain Management
- Bronchopulmonary Dysplasia Treatment Market
- RVO Market Beyond Lucentis and Eylea
- Role of Nanobots in Healthcare
- Wilson’s Disease Pipeline Therapies
- denovoSkin – Personalized Skin Grafts for Burn Treatment
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.